Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Baricitinib vs. Tocilizumab.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026

Same author

2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Antiviral Treatment for Mild to Moderate COVID-19 in Adults.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026

Same author

Burden of adverse transplant outcomes in kidney transplant recipients with COVID-19 and invasive fungal infections: a retrospective cohort study.

BMC infectious diseases·2026

Same author

COVID-19 convalescent plasma safety and efficacy analysis for biologics license application approval.

Expert review of anti-infective therapy·2026

Same author

Corticosteroid Therapy and Long-Term Outcomes of Post-Infectious Inflammatory Syndrome in Non-HIV Immunosuppressed Cryptococcal Meningitis: A Multicenter Case Series.

The Journal of infectious diseases·2026

Same author

Clinical trial coordination of multifaceted ethical and regulatory oversight entities during the COVID-19 public health emergency.

Contemporary clinical trials·2025

Search research articles

Related Experiment Video

Updated: Jun 17, 2025

Automated Cell Enrichment of Cytomegalovirus-specific T cells for Clinical Applications using the Cytokine-capture System

Automated Cell Enrichment of Cytomegalovirus-specific T cells for Clinical Applications using the Cytokine-capture System

Published on: October 5, 2015

Convalescent Plasma for Immunocompromised Patients.

Shmuel Shoham¹

¹Department of Medicine, Johns Hopkins School of Medicine, 1830 East Monument St., Room 447, Baltimore, MD, 21205, USA. sshoham1@jhmi.edu.

Current Topics in Microbiology and Immunology

|August 8, 2024

Summary

This summary is machine-generated.

COVID-19 convalescent plasma (CCP) offers a vital treatment for immunocompromised individuals battling COVID-19. Evidence supports its use for both acute and persistent infections in these vulnerable patients.

Keywords:

COVID-19 Convalescent plasma Immunocompromised Leukemia Lymphoma SARS-CoV-2 Transplant

More Related Videos

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant

Published on: May 27, 2011

Platelet-Rich Plasma Lysate for Treatment of Eye Surface Diseases

Platelet-Rich Plasma Lysate for Treatment of Eye Surface Diseases

Published on: August 2, 2022

Related Experiment Videos

Last Updated: Jun 17, 2025

Automated Cell Enrichment of Cytomegalovirus-specific T cells for Clinical Applications using the Cytokine-capture System

Automated Cell Enrichment of Cytomegalovirus-specific T cells for Clinical Applications using the Cytokine-capture System

Published on: October 5, 2015

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant

Published on: May 27, 2011

Platelet-Rich Plasma Lysate for Treatment of Eye Surface Diseases

Platelet-Rich Plasma Lysate for Treatment of Eye Surface Diseases

Published on: August 2, 2022

Area of Science:

Immunology
Infectious Diseases
Hematology

Background:

Immunocompromised patients face heightened risks of severe COVID-19 complications.
Persistent infections can occur in this population, necessitating effective therapeutic strategies.

Purpose of the Study:

To review the rationale and evidence for using COVID-19 convalescent plasma (CCP) in immunocompromised patients.
To assess the efficacy of CCP in treating both acute and persistent COVID-19 infections.

Main Methods:

Literature review encompassing case series, comparative studies, randomized trials, and systematic reviews.
Analysis of historical data and mechanistic understanding of antibody treatments.
Inclusion of recommendations from multiple practice guidelines.

Main Results:

Evidence from various study types supports the use of CCP in immunocompromised patients.
CCP demonstrates value in managing both acute and persistent COVID-19 infections.
Mechanisms of antibody action and historical precedent bolster the therapeutic rationale.

Conclusions:

COVID-19 convalescent plasma is a significant therapeutic option for immunocompromised patients.
The review consolidates evidence and guidelines for CCP application in this patient group.
Further research and guideline adherence are crucial for optimal patient outcomes.